The management ofthe NOneck in patients with head and neck canc er is controv ersial. Neck dissection pro vides important staging information that guides pati ent treatment. We examined thefeasibility ofusing a dye technique for staging patients by sentine l lymph node biopsy (SLNBX). We studied seven patients with previously untreated early-stage squam ous cell carci noma of the oral cavity and NO necks. Each patient underw ent SLNBX guid ed by an intraoperative injection of 1% isosulfan blue dye. An open biop sy ofthe sentinel node was followed by neck dissection. We identifi ed the sentinel node info ur of the seven patients (57%). The sentinel node accurately predicted the pathologic status of the neck in three of these four patients (75 %).1n one ofthe three patients, the sentinel node was one offour histopathologically positive nodes , whereas in two others , the neck wasfree ofdiseas e. One patient had a histopathologically negative sentin el node and tumor metastasis present in the neck. Ojthef our 166 * Admin istered as 240 mg bid for 14 days (n; 144). There is no evidence Ihot doses higher than those recommended are more effective. t Cloritin [lorolo dine] is nonsedoting 01 the recommended dose of 10 mg once daily.
patients in whom a sentinel node was identifi ed, the negative predictive value for the absence of cervical meta stases was 67%. Based on ourfindings and those of other autho rs, we conclude that the use of blue dye in lymphatic mapping for SLNBX in head and neck cance r patients is technically fea sible but of limit ed clini cal utility. Our literature review also sugges ts that perf orming SLNBX with a radiotracer technique ora combination of a radiotracer and blue dye is a promising method of staging the NOneck in head and neck cancer patients and warrants f urther clinical study.
Introduct ion
Sentinel lymph node biopsy (SLNBX) has become an accepted technique for determining whether metastases are present in the first extratumoral echelon of draining lymph nodes in melanoma and breast cancer patients. SLNBX has allowed these patients to avoid procedural morbidity while undergoing staging for their malignancies. If this technique could be shown to be applicable to headand neck cancer, it wouldrepresent a major advancement in staging these patients.
The objectiveof this study was to evaluate the feasibility of SLNBX by using an isosulfan blue dye lymphatic mapping technique in patients with squamous cell carcinoma of the oral cavity. A secondary objective was to review the results of this study within the context of the current literature.
Pat ients and methods
The eligibilitycriteria for participationin this prospective study were a diagnosis of previously untreated, biopsyprovensquamous cell carcinomaof the oral cavity and no clinical evidence of neck disease. Patients who had a history of a dye reaction or severe asthma were excluded from the study. From December 2000 through July 200I, we enrolled seven consecutive patients-three men and four women, aged 41 to 77 years (mean: 65). The primary tumor was located in the oral tonguein five patients, in the floor of the mouthin one patient, and in the alveolar ridge in one patient (table I) .
Lymphatic mapping was carried out after each patient was placed under general anesthesia. We injected 1.5 ml of 1% isosulfan blue dye into the submucosa beneath and circumferentially around the primary tumor. A supraomohyoid neck dissection was then performed on the side ipsilateral to the tumor. A subplatysmal skin flap was first raised, and all lymphatic tissue was closely examined for blue staining. Any lymph node that stained blue was considered to be a sentinel node (figure). The • The O N LY 2 nd-generation a ntihistamine that's proven to be no nsedating even at more than twice the reco mmended qd dose'"""
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Results
T he sentinel node was identified in four of the seven patients (57 %), and it accurately predicted the pathologic status of the neck in three of the four (75 %). The negative predictive val ue for the absence of cervical metastases in the four patients was 67 %. We also evaluated da ta with respect to the primary tumor location, sentinel node location, and pa thologic findings (table 2) . One pa tient (pa tient 4) ha d a histopatho logically negative sentinel node, but disease was present in her neck dissection specimen. In one patient (patient 2) , the sentinel node was one of four histopathologically positive nodes, whereas in two others (patients I and 3), the neck was free of disease. Sentinel nodes were not identified in three patients-one whose tumor was in the tongue (pa tien t 5), the patient whose tumor invol ved the floor of the mouth (patient 6), and the patient whose tumor involved the alveolar ridge (patient 7). None of these three patients had metastatic disease in the neck dissection specimen. The localization of sentinel nodes with isosulfan blue dye req uired additional operative time. It took approximately 15 extra minutes to inject the dye , localize the node, and dissect it free . Reported complications of dye injection, which include infection and allergic reaction, I were no t observed in our study.
Discussion
In patients who have head and neck sq uamous cell carcino ma (HNSCC), the presence of nodal disease-either gross or microscopic-remains the most important factor in predicting disease recurrence and survival.i? T he presence of nodal metastases can shorten 5-year survival by as Obtaining computed tomography or magnetic resonance imaging of the neck does not significantly improve the detection of occult disease. " Pathologic evaluation of the neck dissection specimen is considered to be the gold standard for neck node evaluation. Approximately twothi rds of early-stage NO patients who undergo neck dissection (and incur its associated morbidity) have no pathologic evidence of disease." Potential complications of neck dissection include scarring, paresthesia, seroma, infection, pain, limitation of shoulder range of motion, deformity, and death. Failure to perform a dissection in favor of taking a wait-and-see approach in these patients can lead to disease recurrence and worsen the prognosis."
The ideal neck-staging tec hnique would allow for an accurate evaluation of nodal status whi le avoiding overor undertreatment of the neck. SLNBX potentially allows for the accurate staging of patients with HNSCC and NO necks while avoiding neck dissection.
Despite controversy regarding its specific definition, "
Morton et aI's definition of a sentinel node as "the initial lymph node upon which the primary tumor drains"!" is perhaps the most universally applicable. Lymphatic metastases do not occur randomly but predictably, in accordance with the pre-existing lymphatic anatomy. The sentinel node represents the first extratumoral echelon of nodes to receive metastases. The practice of staging or selective neck dissection-carried out by removing nodal levels that have the highest probability of harbori ng metastatic disease-is based on the res ults of stud ies that examined the patterns and freq uency of neck nodal me- Levell (n = 1); level 2 (n = 2)
tastases in large patient popul ation s.v":" Unli ke selective neck dissection, sentinel node biops y has the adva ntage of allow ing for the direct evaluation of the first lymphatic drainage basin of a specific patient ' s tumo r. Th e first descr ipti on of contemporary SLNBX techniques being carried out on an HNSCC patient was reported in 1996 by Alex and Krag. 16 The SLNBX was performed on an NO pati ent ju st prior to surgical treatment of a suprag lottic laryn geal cancer. Intr aoperati vely, technetium-99m (Tc-99m) sulfur coll oid was injected around the tum or, and gamm a-probe guid ance was used to identify the sentinel node, which correctly predicted the pre senc e of neck nodal disease in this patient. Prior to this report , Iymph oscintigraphy was found to be ofl imited diagnostic benefit in patient s with head and neck cancer.l':" Th ree meth odol ogies have been used to perform SLNBX (table 3) y -J6 Th ese tec hniques are broadly classified as invol ving ( I) the use of a radiotracer, (2) the use of a vital dye, and (3) the use of both together. Th e rad iotr acer techn iqu e, with lymph oscintigrap hy and intr aoperative ga mma-probe-assisted localization , has bee n used by a number of inves tiga tors .P? Koch et al per for med SLNBX on five NOpatien ts who had squamous ce ll carci no ma of the oral cavi ty and oro pharynx .26 T hey injec ted Tc-99m sulfur co lloid intramucosally aro und the pri mary tum or. T he sentine l node was identified in two of these five patient s (40 %), and it acc urate ly pred icted the disease status of the neck in both . Sentinel nodes were not ide ntified in the other th ree patie nts despi te the presen ce of microscopic metastatic di sease in two of them. Koch et al offered two possi ble ex planations for their poor sentinel lym ph node identifi cation rate. One of their patient s had a history of radiation treatment, whic h, they wro te, ca n "alter the know n lymph atic cha nnels rend er ing Iymphoscintigr aph y ineffective. " A second patient in thi s study was described as having a " thick neck"-a neck in which gross nod al metastases were not clin icall y detectabl e-and th is was another reason the authors be lieved that the acc uracy of SLNBX was limi ted.
CLINICAL INSTRUCTOR, SKULL BASE INSTITUTE
In six subse quent studies, the radio tracer techn ique wit h preop erative Iymphoscinti graph y and int raop erat ive gamma-pro be guidance was perfo rmed on 44 patie nts with NO HNSCC y -· n Primary tum or sites included the ora l cavi ty , oro phary nx, hypoph arynx, and larynx. Se ntinellymph nodes were iden tified in all 44 patient s, and in eac h case they cor rec tly predicted the lymph node stat us of the neck. In one of these studies, Chiesa et al used the radi otracer tech nique to perform SL N BX on II patien ts who had clinically NO necks." First they resec ted the primary tum or in al1 pa tients. One mo nth later, they performe d SLN BX by injecting the area aro und the scar tha t res ulted fro m the pri mary tum or resection. Sentinel nodes were ide ntifie d in all patients. Of the eight patient s who eve ntua lly underwent neck dis sec tion, Iymph oscintigraph y was performed on five prior to the primary rese ct ion. Chiesa et al then co mpare d these Iymphosc intigraph ic findings with those that had bee n obtained during the SLNBX. Thi s com parison demonstrated th at the pattern of lymph atic drai nage fro m the primary tum or site had been altered by its resection . Regardless of th is, in al1 eig ht patien ts who underwent neck dissection in this series, the senti nel nodes acc urately pred icted the pathologic status of the neck.
Co lnot et al emp loye d a radiotracer tecjm ique along with ultr asoun d-gu ided fine-need le aspi ratio n biopsy to identi fy senti ne l lymph nodes in a total of 12 HNSCC Are you looking for more? more opportunities . .
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Call us today at 800.365.8900 and put one of our consultants to work for you. patients ." Sentinel nodes were identified in all six of the patients who underwent neck dissection, and all of these nodes accurately predicted the pathologic status of the neck. Furthermore, the fine-needle aspiration biopsy specimens also correctly predicted the pathologic status of the neck, although its use was limited by its inability to aspirate small « 2 mm) sentinel nodes. In addition to our series of seven patients, two other series have described the use of vital dye alone for the identification of sentinel nodes in HNSCC. Pitman et al performed SLNBX on 16 HNSCC patients who had primary tumors in the oral cavity, oropharynx, hypopharynx, and larynx ." Nine of these patients had NO necks. However, the results of this study were disappointing in that no sentinel lymph node had been identified in any patient. Shoaib et al also reported disappointing results after using vital dye alone." They performed SLNBX on 25 HNSCC patients who had primary tumors of the oral cavity or oropharynx. Of these 25 patients , 13 underwent SLNBX with Patent Blue V dye alone. Of these 13 patients, seven were N+ and six were NO. The six NO patients underwent neck dissection. Sentinel lymph nodes were identified in four of the six (67 %), and they correctly predicted the pathologic status of the neck in only two of the four (50%). In the remaining 12 patients , Shoaib et al also carried out SLNBX with a combination dye and radiotracer technique. Ten of these patients were included in a subsequent report by Shoaib et al (described later in this article) ."
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The combined use of radiocolloid and dye for SLNBX 160 in HNSCC has been described in three reports.P:" Bilch ik et al used radiotracer and isosulfan blue dye on five patients who had primary tumors of the oral cavity , and they identified a sentinel node in all five ." However, neck dissection was carried out only in the one patient who had a positive sentinel node. It is uncle ar from this study whether the sentinel node was iden tified by the dye, by the radiocolloid, or by a combination of both . Shoaib et al performed SLNBX on 39 NO patients and one NX patient with squamous cell carcinoma of the oral cavity or oropharynx." (This series included the nine NO patients and one NX patient who had been described in their previous report.") They combined preoperative lymphoscintigraphy with intraoperative gamma -probe guidance and Patent Blue V dye. The radiocolloid they used was Tc-99m-labeled colloidal human serum albumin. The sentinel node was identified in 36 of 40 patients (90%), and it correctly predicted the nodal status of the neck in 35 of the 36 (97%). The one patient who had a false-negative lymph node (the sentinel node was identified and found to be free of tumor, but tumor was present in the neck dissection specimen) was found to have an extensive T4 tumor of the floor of the mouth . Shoaib et al attributed this false negative to the extent of the lesion and to their inability to fully encompass the tumor during radiotracer and dye injection. In this series , the radiocolloid and the blue dye techn iques complemented one another. Of the total of 41 sentinel nodes that were found, 15 (37%) were identified by the radiotracer alone, five (12%) were identified by the dye alone , and 21 (51%) 
WARNING: The replacement of a systemic corticosteroid with a topical corticosteroid can be accompanied by signs of adrenal insufficiency.
In clinical trials, using the recommended dose, the overall incidence of adverse events was comparable to vehicle placebo. The most commonly reported adverse events , not necessarily drug related , were, for NASONEXo and vehicle placebo, respectively: headache (17-26% vs 18-22%), viral infection (8-14% vs 9-11%), pharyngitis (10-12% vs 10%), epistaxis/blood-tinged mucus (8-11% vs 6-9%), and coughing (7-13% vs 6-15%). Other adverse events which occurredinlessthan 5% but greater than or equal to 2% of mometasone furoate adult and ado lescent patients (ages 12years andol der) treatedwi th200-mcg doses(regardlessofrelat ionship to t re a t m en t) , a nd m o ref re qu e n t~t h ani n th epl a ceb o g ro u pin c l ud e d: a rt h ra l g i a , asthma, bronchitis, chest pain, conjunc tivitis, diarrhea, dyspeps ia, earache, flu-likesymptoms, myalgia,nausea, and rhinllis.
Other adverse events whic hoccurredin lessthan5%butgreater than or equalto2% ofmometasone furoate pediatncpatientsages 3to11 years treat-edlVith100-mcg doses vs placebo (regardless of relationship totreatment) and more l req u e n t~than inthe placebogroup included: diar rhea, nasal irritation, otit ismedia, andwheezing.
Rarecases of nasal ulcers andnasal andoral candidiasis were also reportedinpatientstreated wllh NASONEX Nasal Spray, 50meg, p r i m a n~inpa tients treated forlonger than 4weeks.
In postmart<eting sUlVeiliance ofthisproduct, cases ofnasal burning and irntation,anaphylaxis andangioedema, andrarecasesofnasal septal pertorationhave been reported. OVERDOSAGE Ther eare nodataavailableon the effects ofacute orchronic overdosage wllhNASONEX Nasal Spray, 50 meg. Because oflow systemic bioavailability, and an absence of acute drug-relat ed systemic findings in clinical studies, overdose isunl i ke~tore quireany therapy other thanobservaton. Intranasal administration of1600meg (8times therecommended dose ofNASONEX Nasal Spray, 50meg) d a i~for29days, tohealthy human volunteers, was well toleratedwith noincreased incidence of adverse events.Single intranasal doses upto4000 meg havebeen studiedinhuman vol unt eerswith noadverse effects reported. Single oral dosesupto8000meghavebeenstudiedinhuman volunteers with noadverse effects report ed. Chronicoverdosage withany corticosteroid may result insigns or symptoms ofhypercorticism (see PRECAUTIONS).Acuteoverdosage \'iththisdosage form isunl i ke~since one bottleofNASONEX Nasal Spray, 50meg contains approxrnately B500 mcg ofmometasone furoate.
Seven hundred and~v e n t y (720) patients3to11years ofage wer etreated with mometasone furoatenasal spray, 50meg (100 meg total dai~dose) in controlledclinical tnals. Safety and effectiveness inchildren lessthan 3years ofage have not beenestablished.
Aclinicai study has been conducted for1 year in pediatric patients (ages 3to9years) toassess the effect of NASONEX Nasal Spray, 50meg (100meg total d a i~dose) on grol'Ah velocity.No s t a t i s t i cal signilicant effect on grolh velocity was observed forNASONEX Nasal Spray, 50meg comparedtoplacebo. No e~dence ofcl i n i cal relevant HPAaxis suppression was observed fol-lowinga3D-minute Cosyntropin infusion.
The potential ofNASONEX Nasal Spray, 50meg tocause grolh suppressioninsusceptiblepatients orwhen given athigherdoses cannot be ruled out Ger iafric Use: Atotal of 203 patients above 64 years of age (age range 64toB5 years) have been treated with NASONEX Nasal Spray, 50meg forup to3months.Theadverse reactions report edinthispopuancn were similar in type andincidence tothose reportedbyyounger patients. ADVERSE REAC TIONS Incontrolled US and Intemational cl inical studies, a total of3210adult and adolescent palient s ages 12years andolder received treatmentwith NASONEX Nasal Spray, 50meg atdoses of50toBOO meg/day. Thernajority ofpatients(n= 2103) were treated with 200 meg/day. In controlled USand Inter national studies, atotal of990 pediani cpatients(ages 3to 11 years) receivedtreatment wll hNASONEX Nasal Spray, 50 meg, atdoses 01 25to200 meg/day. The majorityofpediat ncpatients (720) lVere trealed wil h 100 meg/ day.Atotal of513aM ,adclescent,andpediatnc patientshave been treatedfor1year orlonger.Theoverall incidence ofadverse events for patients treated with NASONEX Nasai Spray, 50meg was comparable topatients treated with the vehicleplacebo. ,AJso, adverseevents did not differ si gn i l i cantb asedon age,sex, orrace.Three percentorless ofpatients inclinicaltnals discontinued treatmentbecause ofadverse events; thisrate was similarfor the vehicleand active comparators.
Alladverse events (regardless of relationship totreatment) reported by5% ormore ofadull andadolescent patients ages 12years andolderwho received NASONEX Nasal Spray, 50meg, 200 meg/day andbypedialri cpatients ages 3 to11 years who receivedNASONEX Nasal Spray, 50meg, 100 meg/day in clinical tnals vs placebo andthat were more common with NASONEX Nasal Spray, 50megthanplacebo, are displayed inthetablebelow. one single-dose, parallel -groupstudy of patientsinanoutdoor "park" setting (part< study) and one environmental exposure unit (EEU) study and within 2days after the first dose intwo randomized,double-blind, placebo-controlled, parallel-group seasonal allergic rhinitisstudies. Maximum benefit is u s ua lã chieved within1to2weeks afterinitiationofdosing. Patientsshouldtake the medication as directed andshouldnot increasethe prescnbeddosage byus ing itmore thanonce aday inan attempt toincr easerts effectiveness. Patients should contact their physicianif symptoms donot improve, orif the condition worsens. To assure proper use of this nasal spray, and to attain maximum benetif,patientsshouldread and follow the accompanyingPatient' s InstructionsforUse carel u l~. Patients shouldbe cautioned not tospray NASONEX Nasal Spray, 50meg into the eyes ord i rect~onto thenasal septum.
ADVERSEEVENTS FROMCONTROLLED
Persons who are onimmunosuppressant doses of corticosteroids should be warned toavoid exposure to chickenpox ormeasles,and patients should also be ad~sed that il they are exposed, medical advice shouldbe sought without delay.
Carcinogenesis, Mufagenesis,Impairment ofFertility: Ina2-yearcarcinogenicitystudy 01 Sprague Dawley rats, mometasone furoate demostrated no st at i st i cal significant increase oftumors atinhalationdoses upto67mcglkg (approx i mate~3 and 2 times the maximum recommended da ĩ intranasal dose inadultsandchildren, respecti ve~, onamcg/m' basis). Ina19-month carcinogenicitystudy ofSwiss CO-I mice,mometasone furoate demonstrated no statist ically significant increase inthe incidence of tumors at in halation doses upto160mcglkg (approx imate~4 and3times themaximumrecommendedda i~intrana sal dose inadults andchildren, re s pec t i v e~, on amcg/m' basis).
At cytotoxic doses, mometasone furoate produced an increaseinchromosome aberrations invi tro inChinese hamster ovary-cell culturesin the nonactivation phase,but not inthepresence ofratliverS9 fraction.Mometasone furoatewas not mutagenicinthe rnouse-srnpnorna assay and the salmo-neffaIE. colVmammalian microsome mutationassay, aChinese hamsterlung cell (CHL)chromosomal-aberrations assay, an in vivo mouse bone-marrow erythrocyte-micronucleus assay, arat bone-marrowclastogenicity assay, and the mouse malegerm-cellclastogenicity assay.Mometasone furoatealso di d not induce unscheduledONAsynthesisinvi vo inrat hepatocytes.
Inreproductive studies inra ts, impairment offertililywas not producedby subcutaneous doses upto15mcglkg (l essthan the maximum recommended dai~int ranasal dose in adults on a mcg/ m' basis) . However, mometasone furoate caused prolonged gestation, prolonged and diffi cult labor , reduced offspr ing sulVival, and reduced mater nal body weight gain at a dose of 15mcglk g.
Pregnancy : Tenltogenlc Effects: Pregnancy Category C : Mometasone furoate causedcleft palateinmice atsubcutaneous dosesof60 mcglkg and above (ap p ro~mate~2 fimes the maximum recommended daĩ intranasal dose inadulls on a mcg/m' basis). Offspnng sulVival was reduced in the 180mcglk ggroup (ap p roxi mate~4times the maximum recommended d a iĩ ntranasal dose inadultsonamcg/m' basis) . Nosuch effects were observed at 20mcglkg(less than the maximumrecommended da ĩ intranasal dose in acuhs on amcg/ m' basis).
. Inrabbits,mometasonefuroate caused fiexedfrontpaws atatopical der mal dose 01 150 mcglkg (ap p rox imate~14 times the maximum recommended da ĩ intranasal dose inadults on amcg/ m' basis).
In rats, mometasone fur oate produced umbi lical hemia, cleft palate, and delayed ossification atatopi cal dermal dose of 600 mcglkg (ap prox imate3 0times the maximum recommended da ĩ intranasal dose in adulls on a mcg/m' basis). At 1200 mcglkg (ap prox i mate~60 times the maximum recommended d ai~intranasal dose inadultson amcg/ m'basis), microphthalmia, umbilicalhernias,anddelayedossification were observed in rat pups.
Inthese devel opmental studies,ther ewere also reductions inmaternal body weight gain and effects on fetal growth (lowerfetal body lVeights and/or delayedossllication) inmice (60 and180mcglkg), rabbns (150 mcglkg), and rats (600 mcglkg).
Inanoral developmental studyinrabbits, at 700mcglk g, (a p prox imate~70 times themaximumrecommendeddaily intranasaldose inadutls on amcglm l basis), increasedinci dencesofresorptions andmalformations, includingcleft palate and/or head malformations (hy droce pha~or domed head) were observed, Pregnancyfailure was observed inmost rabbits at2Boomcglkg (approxi mate~27 0times themaximum recommended dai~intranasal dose in adults onamcg/m' basis).
There are no adequate and well-controlled studies in pregnant women. NASONEX Nasal Spray, 50 meg, like other corticosteroids, should beused dunngpregnancyo n~if thepotent ial benefitsjust ifythe pot ential nsktothe fetus. Experi encewith oral corticosteroids since theirintrod uction in pharmacologic, as opposed to physiologic, doses suggests that rodents are more prone to teratogenic effects from corticosteroi dsthan humans. Inaddition, because there isanatural increase incorticosteroidproduction duringpregnancy, most women will require alower exogenous corticosteroiddoseand many will notneed corticosteroidtreatment dunngpregnancy .
Nonteratogenic Effects: Hypoadrenalism may occur in infants born to women receiving corticosteroids duri ng pregnancy. Suchinfants shouldbe caref ul moni tored.
Nursing Mothers: It is not known iI mometasone fur oate is excreted in human milk. B ecause other corticosteroids are excreted in human milk, caution shouid be usedwhen NASONEX Nasal Spray, 50meg isadministered tonursing women.
Pediatric Use: Cont rolled clinical studies have shown intranasal corticosteroids may cause areduction in grovAh velocity inpediatric patients. This effect has been observed inthe absence oflaboratoryevidence ofhypothalamic-pit uitary-adrenal (HPA) axis suppression, suggesting that grol'Ah velocity isamore sensitive indicator ofsystemic corticosteroidexposure inpediatric patients thansome common~used tests ofHPAaxisfunction. The long-term effects of this reduction ingrOl'Ah veloclly associated with int ranasal corticosteroids,includingtheimpact onfinal adult height, are unknown. Thepotential for"calch up" growth following discontinuation oftreatment wi thintranasal corticosteroids has not been adequate~studied. The growth of pediatri c patients receiving intranasal corticosteroids, includi ng NASONEX Nasal Spray, 50 megshouldbemonitored rou t i ne~(eg,viastadiometiY).Thepotential growth effects of prolongedtreatment shoul dbe weighedagainst clinical benefits obtained and the availability of safeand effective noncorticosteroid treatment a«ematives. Tominimizethe systemiceffects ofintranasalcort icosteroids, including NASONEX Nasal Spray, 50meg, each patient shouldbe tt ratedtohislher lowest eff ective dose.
were simultaneously identified by the radiotracer and dye . Thus , in this study , the combination was more accurate than either technique alone .
Finally, Moz zillo et al carried out SLNBX on 41 NO patie nts who had squamous cell carcinoma of the oral cavity." The y too used preoperative lymphoscintigraphy, intraoperative gamma-probe guidance, and Patent Blue V dye. The sentine l node was identified in 39 of the 41 patie nts (95 %). It is interesting that seven of the 39 patients (18 %) had sentinel lymph nodes located at neck levels 4 or 5.
In concl usion , SLNBX carried out on clinically NO patients who have HNSCC represents a potential advance over selective dissection as an accurate method of neck staging. Th e SLNBX technique will reduce cost, time , and morbidity by decreasing the number of dissections that are performed on NOnecks . Another potential benefit of SLN BX is that it can ident ify the small number of patients who harbor meta static disease outside the levels that are removed by selective dissection. Although the numbers of patients in our series and in others are small and the clin ical experience with this tech nique is limited, the efficacy of SLNBX for staging HNSCC appears to be comparable to that for staging other cancers .
Even so, before SLNBX becomes an accep ted staging proce dure , several issues must be addressed. These issues include a determination of which head and neck subsites and tumor stages are most appropriate for this technique. Moreover, the optimal method of performing this procedure remains to be defined. Finally, judging from the results of all the case series reviewed here , the use of a blue dye technique alone for SLNBX in HNSCC patients, while technically feasible, is of limi ted clinical utili ty, altho ugh it might emerge as an important adjunct to the radiotracer technique. If these issues can be resolved, it appears to us that the use of SLNBX for staging HNSCC is promising and warra nts further study in future clinical trials .
